Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41:111–88. https://doi.org/10.1093/eurheartj/ehz455.

Article  PubMed  Google Scholar 

Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, Claeys MJ, Dan GA, Dweck MR, Galbraith M, Gilard M, Hinterbuchner L, Jankowska EA, Jüni P, Kimura T, Kunadian V, Leosdottir M, Lorusso R, Pedretti RFE, Rigopoulos AG, Rubini Gimenez M, Thiele H, Vranckx P, Wassmann S, Wenger NK, Ibanez B, ESC Scientific Document Group. 2023 ESC guidelines for the management of acute coronary syndromes. 2023 ESC guidelines for the management of acute coronary syndromes. 2023, 44, 3720–826, https://doi.org/10.1093/ehjacc/zuad107

Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, Hegele RA, Krauss RM, Raal FJ, Schunkert H, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38:2459–72. https://doi.org/10.1093/eurheartj/ehx144.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Biccirè FG, Häner J, Losdat S, Ueki Y, Shibutani H, Otsuka T, Kakizaki R, Hofbauer TM, van Geuns RJ, Stortecky S, et al. Concomitant coronary atheroma regression and stabilization in response to lipid-lowering therapy. J Am Coll Cardiol. 2023;82:1737–47. https://doi.org/10.1016/j.jacc.2023.08.019.

Article  CAS  PubMed  Google Scholar 

Silverman MG, Ference BA, Im K, Wiviott SD, Giugliano RP, Grundy SM, Braunwald E. Sabatine. Association between lowering LDL-C and Cardiovascular Risk Reduction among different therapeutic interventions: a systematic review and Meta-analysis. JAMA. 2016;316:1289–97. https://doi.org/10.1001/jama.2016.13985.

Article  CAS  PubMed  Google Scholar 

Bulluck H, Foin N, Tan JW, Low AF, Sezer M, Hausenloy DJ. Invasive Assessment of the Coronary Microcirculation in Reperfused ST-Segment-Elevation myocardial infarction patients: where do we stand? Circulation. Cardiovasc Interventions. 2017;10. https://doi.org/10.1161/circinterventions.116.004373.

Navarese EP, Kolodziejczak M, Winter MP, Alimohammadi A, Lang IM, Buffon A, Lip GY, Siller-Matula JM. Association of PCSK9 with platelet reactivity in patients with acute coronary syndrome treated with prasugrel or ticagrelor: the PCSK9-REACT study. Int J Cardiol. 2017;227:644–9. https://doi.org/10.1016/j.ijcard.2016.10.084.

Article  PubMed  Google Scholar 

Navarese EP, Kolodziejczak M, Kereiakes DJ, Tantry US, O’Connor C. and P. A. Gurbel. Proprotein Convertase Subtilisin/Kexin type 9 monoclonal antibodies for Acute Coronary Syndrome: a narrative review. Annals of internal medicine 2016, 164, 600–7, https://doi.org/10.7326/m15-2994

Nicholls SJ, Kataoka Y, Nissen SE, Prati F, Windecker S, Puri R, Hucko T, Aradi D, Herrman JR, Hermanides RS, et al. Effect of Evolocumab on Coronary Plaque phenotype and burden in statin-treated patients following myocardial infarction. JACC Cardiovasc Imaging. 2022;15:1308–21. https://doi.org/10.1016/j.jcmg.2022.03.002.

Article  PubMed  Google Scholar 

Räber L, Ueki Y, Otsuka T, Losdat S, Häner JD, Lonborg J, Fahrni G, Iglesias JF, van Geuns RJ, Ondracek AS, et al. Effect of Alirocumab added to high-intensity statin therapy on coronary atherosclerosis in patients with Acute myocardial infarction: the PACMAN-AMI Randomized Clinical Trial. JAMA. 2022;327:1771–81. https://doi.org/10.1001/jama.2022.5218.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wu C, Lin D, Ji J, Jiang Y, Jiang F, Wang Y. PCSK9 inhibition regulates Infarction-Induced Cardiac Myofibroblast Transdifferentiation via Notch1 signaling. Cell Biochem Biophys. 2023;81:359–69. https://doi.org/10.1007/s12013-023-01136-1.

Article  CAS  PubMed  Google Scholar 

Qi Z, Hu L, Zhang J, Yang W, Liu X, Jia D, Yao Z, Chang L, Pan G, Zhong H, et al. PCSK9 (Proprotein Convertase Subtilisin/Kexin 9) enhances platelet activation, thrombosis, and myocardial infarct expansion by binding to platelet CD36. Circulation. 2021;143:45–61. https://doi.org/10.1161/circulationaha.120.046290.

Article  CAS  PubMed  Google Scholar 

Franchi F, Ortega-Paz L, Rollini F, Been L, Rivas A, Maaliki N, Zhou X, Pineda AM, Suryadevara S, Soffer D et al. Impact of evolocumab on the pharmacodynamic profiles of clopidogrel in patients with atherosclerotic cardiovascular disease: a randomised, double-blind, placebo-controlled study. EuroIntervention: journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology 2023, 18, 1254–65, https://doi.org/10.4244/eij-d-22-00719

Xu Q, Zhao YM, He NQ, Gao R, Xu WX, Zhuo XJ, Ren Z, Wu CY, Liu LS. PCSK9: a emerging participant in heart failure. Volume 158. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie; 2023. p. 114106. https://doi.org/10.1016/j.biopha.2022.114106.

Tiller C, Holzknecht M. Association of circulating PCSK9 with Ischemia-Reperfusion Injury in Acute ST-Elevation myocardial infarction. 2024, 17, e016482, https://doi.org/10.1161/circimaging.123.016482

Ding Z, Wang X, Liu S, Shahanawaz J, Theus S, Fan Y, Deng X, Zhou S. Mehta. PCSK9 expression in the ischaemic heart and its relationship to infarct size, cardiac function, and development of autophagy. Cardiovascular Res. 2018;114:1738–51. https://doi.org/10.1093/cvr/cvy128.

Article  CAS  Google Scholar 

Bhatt DL, Briggs AH, Reed SD, Annemans L, Szarek M, Bittner VA, Diaz R, Goodman SG, Harrington RA, Higuchi K, et al. Cost-effectiveness of Alirocumab in patients with Acute Coronary syndromes: the ODYSSEY OUTCOMES trial. J Am Coll Cardiol. 2020;75:2297–308. https://doi.org/10.1016/j.jacc.2020.03.029.

Article  CAS  PubMed  Google Scholar 

Landmesser U, Lindgren P, Hagström E, van Hout B, Villa G, Pemberton-Ross P, Arellano J, Svensson ME, Sibartie M, Fonarow GC. Cost-effectiveness of proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab in patients with a history of myocardial infarction in Sweden. Eur Heart J Qual care Clin Outcomes. 2022;8:31–8. https://doi.org/10.1093/ehjqcco/qcaa072.

Article  PubMed  Google Scholar